Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | UBE2N | P61088 | 1/20 | 0.44 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | GBA1 | P04062 | 8/20 | 0.40 |
| ▸ | CA1 | P00915 | 2/20 | 0.39 |
| ▸ | CA2 | P00918 | 2/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3369985 | 0.82 | NPC1 (0.44) | KDM4EUBE2NPSMD14NPC1RAB9A | |
| SCHEMBL1156088 | 0.80 | KDM4E (0.49) | KDM4EUBE2NCA1CA2CA9 | |
| SCHEMBL1156187 | 0.80 | KDM4E (0.51) | KDM4EUBE2NCA1CA2RAPGEF4 | |
| SCHEMBL1155931 | 0.78 | KDM4E (0.46) | KDM4EUBE2NCA1CA2CA9 | |
| SCHEMBL25201078 | 0.77 | KDM4E (0.48) | KDM4EUBE2NCA1CA2RAPGEF4 | |
| SCHEMBL1156049 | 0.75 | LMNA (0.44) | KDM4EUBE2NL3MBTL1KMT2ATHRB | |
| SCHEMBL1156391 | 0.75 | KDM4E (0.43) | KDM4EUBE2NCA1CA2RAPGEF4 | |
| SCHEMBL1156086 | 0.73 | KDM4E (0.44) | KDM4EUBE2NCA1CA2RAPGEF4 | |
| SCHEMBL25188149 | 0.72 | KDM4E (0.41) | KDM4EUBE2NCA1CA2CA9 | |
| SCHEMBL3368043 | 0.71 | TUBB4A (0.44) | KDM4EUBE2NCA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1628957-B1 | SULFOPYRROLES | TAKEDA PHARMACEUTICAL (JP) | 2010-09-29 | — | — | EP | disclosed |
| US-7612064-B2 | Sulfopyrroles | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-11-03 | — | — | US | disclosed |
| US-20070060570-A1 | Sulfopyrroles | TALEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-03-15 | — | — | US | disclosed |
| EP-1628957-A1 | SULFOPYRROLES | Takeda Pharmaceutical Company Limited (JP) | 2006-03-01 | — | — | EP | disclosed |
| WO-2004103968-A1 | SULFOPYRROLES | APONETICS AG (CH) | 2004-12-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070060570-A1 | Sulfopyrroles | TYK2, ARSA, SULT2A1 | KDM4E 3031/4885UBE2N 3712/4885PSMD14 3639/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.